Shah Nikita sold $2.6M of AMRX

Shah Nikita (Executive Vice President) sold 146,403 shares of Amneal Pharmaceuticals, Inc. (AMRX) at $17.51 ($2.56M total) on 2026-08-12.

Original reporting
SEC EDGAR · Shah Nikita
Published Aug 13, 2026, 8:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 9:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AMRX
Neutral
high confidence
Mentioned
$AMRX
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AMRXNeutralLow
01

Why it matters

Traders may briefly check for follow-on insider activity or whether other executives filed related transactions, but the text itself does not introduce a new fundamental catalyst.

02

Market read

A disclosed insider open-market sale worth $2.56M, with no accompanying company news in the provided text.

03

What to watch

The article provides only the sale details; it does not include any concurrent buys, option exercises, or company-specific news that would connect the transaction to performance expectations.

Relevance 6/10Novelty 3/10Timing: filed 2026-08-13 after the 2026-08-12 sale

Background

The article is a SEC Form 4 insider transaction disclosure for Amneal Pharmaceuticals, Inc. (AMRX).

Company-level read

Ticker impact

$AMRXNeutralHigh confidence
Context

Amneal Pharmaceuticals executive vice president Shah Nikita sold 146,403 shares in an open-market transaction worth about $2.56M.

Expected impact

Likely limited near-term impact; any effect would be sentiment-only and typically fades unless paired with other disclosures.

Evidence & confidence

The filing is a disclosed open-market sale, with no 10b5-1 plan and no accompanying company-specific event (earnings, guidance, deal, or regulatory action) in the text.

Market effects

Minimal. Insider sales in pharma are common and do not, by themselves, reset sector expectations.

None indicated.

None indicated.

Counterpoint

The absence of a stated 10b5-1 plan could be misread as bearish, but insider sales often reflect diversification, taxes, or personal liquidity needs rather than outlook.

Key entities

  • Amneal Pharmaceuticals, Inc.

    US-listed pharmaceutical company subject of the Form 4 insider sale disclosure.

  • Shah Nikita

    Executive Vice President who sold 146,403 shares at $17.51 on 2026-08-12.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AMRXHighAI 8/10

Amneal Earnings Call Signals Strong Growth Ahead

Amneal Pharmaceuticals (AMRX) reported Q3 revenue of $863M, up 10% YoY, with adjusted EBITDA rising 30% to $207M and adjusted EPS increasing 53% to $0.26. The company raised its 2026 revenue outlook to $3.15B-$3.25B and adjusted EBITDA guidance to $800M-$815M. Growth was driven by specialty brands, the Kashiv acquisition, and biosimilar platforms, though management noted pressure from AvKARE and temporarily higher leverage.

$AMRXMed

Piper Sandler reiterates Amneal stock rating on earnings beat

Piper Sandler maintained an Overweight rating and $21.00 price target for Amneal Pharmaceuticals (NYSE: AMRX) after its Q3 earnings beat estimates. Amneal reported $0.26 EPS on $862.7M revenue, raising 2026 revenue guidance to $3.15B-$3.25B. Shares are up 78% year-over-year, trading near a 52-week high. Piper Sandler expects steady EBITDA growth and improved leverage ratios.

$AMRXMedAI 8/10

What Amneal Pharmaceuticals (AMRX) Said on Its Q3 Earnings Call

Amneal Pharmaceuticals (AMRX) reported Q3 revenue growth in affordable medicines (19% to $547M) and specialty products (20% to $150M), while AvKARE revenue declined 17% to $165M. Adjusted gross margin increased to 43.2%. The company launched lanreotide, targeting 30-40% market share, and expects significant biosimilar growth. Specialty brands like CREXONT and BREKIYA showed strong performance. Amneal plans manufacturing expansions and aims to reduce leverage below 3x EBITDA by 2028.